Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics

H.C. Wainwright analyst Swayampakula Ramakanth has reiterated their bullish stance on JANX stock, giving a Buy rating on April 17.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors related to Janux Therapeutics’ advancing pipeline and strategic positioning. He highlights the company’s emerging prostate cancer franchise built around three differentiated PSMA-directed bispecifics, which could collectively address patients across multiple disease stages if clinical results continue to be favorable.

He also points to additional value drivers outside prostate cancer, including the EGFR-targeted T cell engager progressing through Phase 1 and the ARM autoimmune platform’s first CD19 program entering clinical testing. In his view, the substantial potential economics from the Bristol Myers Squibb collaboration further validate Janux’s TRACTr technology and help de-risk development, supporting a favorable risk‑reward profile at the current share price.